Research Directory

Investment pendulum swings back towards biotech

Read more

Europe to tackle antimicrobial resistance

Read more

The perilous state of antibiotic development

Read more

Risk sharing with Pharma -- is this the way to go?

Read more

ADCs propelled back into the oncology spotlight

Read more

Why Oxford BioTherapeutics is targeting ADCs

Read more

How developers approach antibody drug conjugates

Read more

The art of tapping into academic expertise

Read more

Making sense of the ECJ's decision on stem cell patents

Read more

Partnering with Russia

Read more